Form 4 for ADMA ADMA BIOLOGICS, INC.
Accepted 2024-08-30 00:00:00 ET · period of report 2024-08-29 · accession 0001140361-24-039821 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-08-30 | 2024-08-29 | ADMA | Grossman Jerrold B | Dir | M - OptEx | $4.28 | +136.9K | 586.2K | +30% | +$585.9K |
| D | 2024-08-30 | 2024-08-29 | ADMA | Grossman Jerrold B | Dir | S - Sale+OE | $17.27 | -136.9K | 467.3K | -23% | -$2.36M |
| DM | 2024-08-30 | 2024-08-29 | ADMA | Grossman Jerrold B | Dir | M - OptEx | $4.28 | -136.9K | 0 | -100% | -$585.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-29 | M | A | 9,000 | $5.96 | 595,166 | D | — | — | |
| 2 | Common | Common Stock | 2024-08-29 | M | A | 9,000 | $10.80 | 604,166 | D | — | — | |
| 3 | Common | Common Stock | 2024-08-29 | M | A | 118,861 | $3.66 | 586,166 | D | — | — | |
| 4 | Common | Common Stock | 2024-08-29 | S | D | 136,861 | $17.27 | 467,305 | D | — | — | (F1) The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 to $17.595. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. (F2) Includes, as of the transaction date, (i) 12,020 restricted stock units granted on February 26, 2024, which will vest in full on February 26, 2025, subject to the Reporting Person's continued service as of the applicable vesting date; and (ii) 455,285 shares of common stock owned by the reporting person. |
| 5 | Derivative | Common Stock | 2024-08-29 | M | D | 9,000 | $10.80 | 0 | D | $10.80 · — to 2025-01-30 | 9,000 Common Stock | (F10) The Reporting Person is exercising these options due, in part, to their near-term expiration date. (F9) These options were granted on January 30, 2015 and vested in twenty-four equal monthly installments, becoming fully vested on January 30, 2017. |
| 6 | Derivative | Common Stock | 2024-08-29 | M | D | 118,861 | $3.66 | 0 | D | $3.66 · — to 2027-06-06 | 118,861 Common Stock | (F7) These options were granted on June 6, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on June 6, 2019. |
| 7 | Derivative | Common Stock | 2024-08-29 | M | D | 9,000 | $5.96 | 0 | D | $5.96 · — to 2026-01-28 | 9,000 Common Stock | (F10) The Reporting Person is exercising these options due, in part, to their near-term expiration date. (F8) These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018. |